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Objectives. The present retrospective analysis of data derived
from a population-based study examined the relationship between
intake of beta-receptor antagonists and plasma concentrations of
the cardiac natriuretic peptides and their second messenger.
Background. Beta-receptor antagonists are widely used for
treatment of cardiovascular disease. In addition to direct effects
on heart rate and cardiac contractility, recent evidence suggests
that beta-receptor antagonists may also modulate the cross talk
between the sympathetic nervous system and the cardiac natri-
uretic peptide system.
Methods. Plasma concentrations of atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP) and their second messen-
ger cyclic guanosine monophosphate (cGMP) were assessed in
addition to anthropometric, hemodynamic and echocardiographic
parameters in a population-based sample (n 5 672), of which 80
subjects used beta-receptor antagonists.
Results. Compared to subjects without medication, subjects
receiving beta-receptor antagonists were characterized by sub-
stantially elevated ANP, BNP and cGMP plasma concentrations
(plus 32%, 89% and 18%, respectively, p < 0.01 each). Analysis of
subgroups revealed that this effect was highly consistent and
present even in the absence of hypertension, left atrial enlarge-
ment, left ventricular hypertrophy or left ventricular dysfunction.
The most prominent increase was observed in a subgroup with
increased left ventricular mass index. By multivariate analysis, a
statistically significant and independent association between beta-
receptor antagonism and ANP, BNP and cGMP concentrations
was confirmed. Such an association could not be demonstrated for
other antihypertensive agents such as angiotensin-converting
enzyme inhibitors or diuretics.
Conclusions. Beta-receptor antagonists appear to augment
plasma ANP, BNP and cGMP concentrations. The current obser-
vation suggests an important contribution of the cardiac natri-
uretic peptide system to the therapeutic mechanism of beta-
receptor antagonists.
(J Am Coll Cardiol 1998;32:1839–44)
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Beta-receptor antagonists are widely used in the treatment of
arterial hypertension and coronary artery disease (1,2). More
recently, beneficial effects have also been demonstrated in
patients with heart failure, including marked improvement in
cardiac function (3–7), and most importantly, a reduction in
mortality (8,9). While the pharmacodynamic mechanisms un-
derlying the antihypertensive and anti-ischemic actions of
beta-receptor antagonists may be sufficiently explained by
direct inhibition of cardiac catecholamine effects with subse-
quent negative inotropy and chronotropy, the mechanisms
responsible for beneficial actions in heart failure are less clear.
In addition to effects on heart rate and cardiac contractility,
stimulation of beta-adrenergic receptors also leads to interac-
tions with other neurohormonal systems. The existence of such
an interaction between the beta-adrenergic system and the
natriuretic peptide system has been proposed by experimental
studies which reported the suppression of cardiac atrial natri-
uretic peptide (ANP)-release in response to beta-adrenergic
stimulation (10,11). Interactions between the beta-adrenergic
and natriuretic peptide systems have also been studied in
patients with hypertension (12,13). An inverse relation be-
tween beta-adrenergic and natriuretic peptide systems was
demonstrated with beta-receptor antagonism, resulting in ele-
vated concentrations of plasma ANP; however, these studies
were short-term trials and included only small groups of
hypertensive patients without control for hemodynamic or
cardiac structural parameters. Furthermore, it remained un-
clear whether beta-receptor antagonism also affects the second
member of the cardiac natriuretic peptide system, brain natri-
uretic peptide (BNP).
The current study was therefore undertaken to further
investigate the association between beta-receptor antagonism
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and ANP, BNP and their second messenger, cyclic guanosine
monophosphate (cGMP), in a population-based sample. We
hypothesized that beta-receptor antagonism would be associ-
ated with a significant, independent augmentation of all mem-
bers of the cardiac natriuretic peptide system.
Methods
Study population. The subjects of this study had initially
participated in the MONICA (Multinational Monitoring of
Trends and Determinants in Cardiovascular Disease) baseline
survey of 1984/85 and its follow-up examination in 1987/88.
Subjects originate from a sex-age-stratified random sample of
all German residents of the Augsburg study area. In 1994, a
second follow-up examination including biochemical and an-
thropometric measurements was offered to a total of 1,010
men and women, aged 50 to 67 years, of whom 672 participated
(14). All subjects provided information on medical history,
physical activities, medication, and personal habits. The infor-
mation on drug therapy was verified by inspection of medica-
tion forms or medications brought to the study center. Body
height and weight were recorded in light clothing, and body
mass index was computed as weight in kg divided by height in
meter squared (kgzm22). Resting blood pressure was measured
three times and the mean used for the study. Arterial hyper-
tension was defined as blood pressure equal or above
160/95 mmHg and normotension was defined as blood pres-
sure below 140/90 mmHg.
Echocardiography. A two-dimensionally guided M-mode
echocardiogram was performed on each subject by one of two
expert sonographers (Sonos 1500, Hewlett Packard, Avondale,
Pennsylvania). M-mode tracings were recorded on stripchart
paper at 50 mmzs21. Only tracings that demonstrated optimal
visualization of left ventricular interfaces were used. To reduce
interobserver variability, all M-mode tracings were analyzed by
a single cardiologist who was blinded for the clinical and
biochemical data. Measurements for M-mode-guided calcula-
tion of left ventricular mass were taken just below the tip of the
mitral valve. Left ventricular internal end diastolic (EDD) and
end systolic diameters (ESD) and septal (Swth) and posterior
wall thickness (Pwth) were measured according to the guide-
lines of the American Society of Echocardiography (15).
Fractional shortening (FS) as a measure of left ventricular
function was calculated as:
FS ~%! 5 ~EDD 2 ESD!/EDD, [1]
Left ventricular mass (LVM) was calculated from M-mode
echocardiograms according to the formula described by
Devereux et al. (16):
LVM ~g! 5 0.8z~1.04z~EDD 1 Swth 1 Pwth!3 2 EDD3! 1 0.6g, [2]
Left ventricular mass was indexed to body surface area as left
ventricular mass index (LVMI) in g m22 body surface area.
Left ventricular hypertrophy by M-mode criteria was des-
ignated when left ventricular mass index was greater than
134 gzm22 body surface area in men and greater than
110 gzm22 body surface area in women (16). Left atrial
enlargement was designated when left atrial diameter was
greater than 45 mm. Systolic left ventricular dysfunction was
designated when fractional shortening was below 28%.
Biochemical measurements. Blood drawn after subjects
were in supine resting position for at least 30 min was
immediately chilled and centrifuged. The plasma was stored at
280°C. ANP, BNP, and cGMP were measured by standard
radioimmunoassay techniques with all determinations per-
formed in duplicate. For measurement of ANP, plasma was
preacidified with acetic acid, extracted on prewashed C-18
columns (Sep-Pak, Waters, Milford, Massachusetts) washed
with Tris-HCl, eluted with acetonitrilammonium acid and
measured with a commercially available antibody (Amersham,
Buckinghamshire, United Kingdom). BNP was measured with
a commercially available RIA-kit (Shionogi, Osaka, Japan)
without cross-reactivity to ANP (17). cGMP was measured
after methanol extraction by a commercially available kit
(NEN, Boston, Massachusetts).
Statistics. The statistical significance of differences in
mean ANP and cGMP concentrations between subjects with
and without beta-receptor antagonists was calculated by the
unpaired t test. Since BNP was not normally distributed,
differences in mean BNP concentrations were compared by the
Mann Whitney U test. Subgroups classified according to
arterial blood pressure, concomitant antihypertensive therapy,
left atrial diameter, left ventricular mass index, and left
ventricular function were compared with the same respective
tests. Testing of subgroups was intended to minimize the risk
of attributing differences between groups to treatment with
beta-receptor antagonists rather than to potential specific
confounders (i.e., bias by treatment indication). Confounders
which often lead to treatment with beta-receptor antagonists
are arterial hypertension, cardiac hypertrophy and, more re-
cently, left ventricular dysfunction. Further statistical testing
was performed employing univariate and multivariate analysis.
Multivariate analysis was performed to determine whether
beta-receptor antagonism was a statistically independent pre-
dictor of the cardiac natriuretic peptide system. These tests
were performed with ANP, BNP, log (BNP) and cGMP as
dependent variables. Together with the multivariate correla-
tion coefficients, the corresponding beta coefficients were
computed. The beta coefficient is an adjusted measure for the
magnitude of change that can be attributed to a given change
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme inhibition
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
cGMP 5 cyclic guanosine monophosphate
EDD 5 end diastolic diameter
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LVMI 5 left ventricular mass index
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in the corresponding predictor. P-values below 0.05 were
defined as statistically significant and p-values below 0.01 as
highly significant.
Results
Characterization of study population. Of the 672 subjects,
80 were treated with beta-receptor antagonists. The different
types of beta-receptor antagonists and the mean doses used are
listed in Table 1. Overall, the prescribed mean dose was 42%
of the recommended maximal dose. Anthropometric, hemody-
namic, and echocardiographic characteristics as well as the
relevant medical history of the studied population are listed in
Table 2. No significant differences between subjects with and
without beta-receptor antagonists were found with respect to
gender distribution, body mass index, history of diabetes or
myocardial infarction and left ventricular function; however,
subjects receiving beta-receptor antagonists were slightly older
and were characterized by lower heart rate, higher systolic and
diastolic blood pressure, greater left atrial diameter and higher
left ventricular mass index. Subjects treated with beta-receptor
antagonists more often received concomitant diuretic therapy
or other antihypertensive therapy but there was no difference
in the use of angiotensin-converting enzyme inhibitors between
groups.
Cardiac natriuretic peptide system and treatment with
beta-receptor antagonists. As compared to untreated individ-
uals, ANP, BNP and cGMP were highly significantly elevated
in subjects treated with beta-receptor antagonists (Fig. 1).
Specifically, ANP was increased by 32% while BNP was
increased by 89% and cGMP was increased by 18%.
Subgroup analysis. This association was further studied in
a number of subgroups (Fig. 2). An augmentation of the
cardiac natriuretic peptides in subjects treated with beta-
receptor antagonists was observed in the presence and absence
of hypertension, in the absence of concomitant antihyperten-
sive therapy, in the presence and absence of left ventricular
Table 2. Anthropometric Characteristics
Without BB With BB
Age (yrs) 57.7 6 0.2 58.7 6 0.4*
Gender (% women) 52.8 51.3
BMI (kgzm22) 27.4 6 0.3 27.0 6 0.7
Diabetes (%) 3.9 3.8
MI (%) 1.5 2.5
ACE-inhibition 5.2 10
Diuretics (%) 7.6 21.5†
Other Rx (%) 7.8 24.1†
Heart rate (min21) 71.2 6 0.5 66.8 6 1.3†
Sys BP (mmHg) 146.4 6 0.8 153.8 6 2.1†
Dia BP (mmHg) 90.5 6 0.5 94.1 6 1.1†
FS (%) 36 6 3 35 6 10
LA diameter (mm) 38.7 6 0.2 40.5 6 0.7†
LVMI (gzm22) 93.2 6 1.3 115.1 6 4.1†
*p , 0.05 vs. without BB, †p , 0.01 vs. without BB. BB 5 beta-receptor
antagonist; BMI 5 body mass index; MI 5 myocardial infarction; other Rx 5
antihypertensive medication except beta-receptor antagonist, angiotensin-
converting enzyme inhibitor or diuretic; Sys BP 5 systolic blood pressure; Dia
BP 5 diastolic blood pressure; FS 5 fractional shortening; LA 5 left atrium;
LVMI 5 left ventricular mass index.
Table 1. Types and Doses of Beta-Receptor Antagonists
Generic Name Subjects (n) Mean Dose (mg)
Metoprolol 24 74 6 9
Bisoprolol 20 6 6 1
Atenolol 17 46 6 9
Propranolol 6 43 6 12
Sotalol 4 160 6 57
Others each 1 or 2
Other beta-receptor antagonists are acebutolol, betaxolol, carteolol, celipro-
lol, nadolol, oxprenolol, and penbutolol.
Figure 1. Atrial natriuretic peptide, brain natriuretic peptide, and
cyclic guanosine monophosphate plasma concentrations were signifi-
cantly elevated in subjects with (black bars) as compared to those
without (hatched bars) beta-receptor antagonism. Differences be-
tween groups may be overestimated by confounding variables (Table
2). ANP and BNP were in pgzml21 and cGMP in pmolzml21. **p ,
0.01 vs. subjects without beta-receptor antagonism.
Figure 2. Subgroup analysis for ANP and BNP plasma concentrations
in subjects with (black bars) and without (hatched bars) beta-receptor
antagonism. RR 5 arterial blood pressure; Rx 5 antihypertensive
therapy; LAd 5 left atrial diameter; LVMI 5 left ventricular mass
index; LV-fct. 5 left ventricular function. *p , 0.05 vs. subjects
without beta-receptor antagonism, **p , 0.01 vs. subjects without
beta-receptor antagonism.
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hypertrophy and in the absence of left atrial distention and left
ventricular dysfunction. The greatest increase was observed in
subjects with left ventricular hypertrophy (ANP 1 36% and
BNP 1 121%). A strong tendency toward increased concen-
trations of BNP in a small subgroup of subjects with left atrial
distention and treatment with beta-receptor antagonists did
not reach statistical significance, most likely due to the small
sample size (n 5 11). An increase in ANP by 22% and BNP by
32% in a small subgroup (n 5 10) of subjects with left
ventricular dysfunction and treatment with beta-receptor an-
tagonists also did not reach statistical significance.
Univariate analysis. By univariate analysis, ANP, BNP and
cGMP concentrations were positively correlated with a num-
ber of anthropometric and cardiac structural and functional
parameters (Table 3).
Multivariate analysis. For multivariate analysis (Table 4),
therapy with beta-receptor antagonists was included into a
multivariate regression model together with the previously
identified predictors as well as angiotensin-converting enzyme
inhibitor therapy, diuretic therapy and therapy with other
antihypertensive agents. Information regarding potential pre-
dictors, including all mentioned echocardiographic parame-
ters, was complete for 462 subjects.
Beta-receptor antagonist therapy was found to be a signif-
icant predictor of ANP, BNP, log (BNP) and cGMP concen-
trations by multivariate analysis. In contrast, neither medica-
tion with angiotensin-converting enzyme inhibitors, diuretics
or other antihypertensive therapies was found to be signifi-
cantly correlated with ANP, BNP, log (BNP) or cGMP plasma
concentrations. Based upon the beta-coefficient, the absolute
increase that appears to be attributed to therapy with beta-
receptor antagonists was 11.2 pgzml21 for ANP, 13.9 pgzml21
for BNP and 0.56 pmolzml21 for cGMP. These absolute
increases correspond to relative increases of 121%, 182% and
117% for ANP, BNP and cGMP, respectively.
In multivariate analysis, systolic blood pressure and left
ventricular mass index were not confirmed as independent
predictors of ANP, left atrial diameter was not confirmed as an
independent predictor of BNP and systolic blood pressure was
not confirmed as an independent predictor of cGMP.
Discussion
The objective of the current study was to investigate the
relationship between beta-receptor antagonism and the car-
diac natriuretic peptide system in a population-based study. A
marked elevation of circulating ANP, BNP and cGMP concen-
trations in subjects treated with beta-receptor antagonists was
observed. Further analysis revealed that this effect was highly
reproducible in a number of different subgroups, independent
of potential confounders, and most prominent in subjects with
left ventricular hypertrophy; thus, the current findings suggest
that chronic treatment with beta-receptor antagonists may lead
to an augmentation of ANP and BNP and that this activation
is functionally relevant because it is associated with increased
concentrations of cGMP, the second messenger of the natri-









BB therapy 0.01/11.2 0.0001/13.9 0.0005/0.23 0.01/0.56
ACE-inhibition p 5 NS p 5 NS p 5 NS p 5 NS
Diuretic therapy p 5 NS p 5 NS p 5 NS p 5 NS
Other Rx p 5 NS p 5 NS p 5 NS p 5 NS
Age (yrs) 0.0001/1.5 0.04/0.59 0.0006/0.02 0.009/0.05
Women vs. men 0.0001/15.1 0.0003/8.6 0.0001/0.19 NI
BMI (kgzm22) NI NI NI 0.0003/20.07
Heart rate (min21) 0.03/20.24 0.01/20.22 0.0003/20.01 0.05/20.01
Sys BP (mmHg) p 5 NS NI NI p 5 NS
LA diameter (mm) 0.02/0.67 p 5 NS NI NI
LV-FS NI 0.01/238.8 0.03/20.68 NI
LVMI (gzm22) p 5 NS 0.004/0.13 0.04/0.002 0.006/0.01
Coeff. 5 coefficient; BB 5 beta blocker; other Rx 5 antihypertensive therapy other than beta blockade,
angiotensin-converting enzyme inhibition or diuretics; yrs 5 years; BMI 5 body mass index; sys BP 5 systolic blood
pressure; LA diameter 5 left atrial diameter; LV-FS 5 left ventricular fractional shortening; LVMI 5 left ventricular
mass index; NI 5 not included because lack of significance in univariate analysis; NS 5 not significant.







Age (yrs) 0.0001/0.22 0.0003/0.15 0.0004/0.14
BMI (kgzm22) p 5 NS p 5 NS 0.003/0.12
Heart rate (min21) 0.02/0.10 0.0005/0.14 0.03/0.09
Sys BP (mmHg) 0.005/0.11 p 5 NS 0.007/0.11
Dia BP (mmHg) p 5 NS p 5 NS p 5 NS
LA diameter (mm) 0.007/0.11 0.03/0.09 p 5 NS
LV-FS p 5 NS 0.02/0.11 p 5 NS
LVMI (gzm22) 0.02/0.11 0.0001/0.21 0.0001/0.17
Yrs 5 years; BMI 5 body mass index; sys BP 5 systolic blood pressure; dia
BP 5 diastolic blood pressure; LA diameter 5 left atrial diameter; LV-FS 5 left
ventricular fractional shortening; LVMI 5 left ventricular mass index; NS 5 not
significant.
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uretic peptide system. Given the benefits of an augmented
natriuretic peptide system, it may further be speculated that
this effect may contribute to the therapeutic action of beta-
receptor antagonists, particularly in left ventricular hypertro-
phy and, possibly, in left ventricular dysfunction.
Potential mechanisms and therapeutic implications. The
present observations appear highly plausible based on in vivo
and in vitro studies which have established important interac-
tions between adrenergic receptor signaling and the synthesis
and release of cardiac natriuretic peptides. In particular,
inhibition of the cardiac natriuretic peptides has been de-
scribed in response to beta-adrenergic stimulation. Specifically,
beta-adrenergic stimulation reduced ANP secretion in cul-
tured myocytes (18) and in vivo, beta-adrenergic stimulation
decreased ANP when isoproterenol was infused locally into
coronary arteries of pigs to stimulate left atrial adrenoceptors
without concomitant changes in atrial filling pressures (10,11).
In contrast, stimulation of the alpha receptor has been shown
to increase ANP secretion in pigs (10,11) and cultured myo-
cytes (18–20), and a stimulatory alpha 1-adrenergic regulatory
sequence has been identified in the 59 flanking region of the
ANP gene (21). Such a stimulatory effect has also been
described for BNP in a study which reported stabilization of
BNP mRNA through alpha-adrenergic activation (22). These
experimental data on differential effects of adrenergic recep-
tors on the cardiac natriuretic peptides may help to explain the
current findings as they emphasize potential effects of beta-
adrenergic receptor antagonists on the balance between alpha-
and beta-adrenergic stimulation which is critical for the regu-
lated secretion of the cardiac natriuretic peptides.
It is tempting to speculate that beta-receptor antagonism-
related augmentation of natriuretic peptides offers a yet un-
recognized therapeutic mechanism for this class of drugs. This
notion is underscored by the elevation of cGMP, the second
messenger for both ANP and BNP. Indeed, exogenous infu-
sion of ANP and BNP has been demonstrated to result in
vasodilatation, natriuresis and diuresis, improved central he-
modynamics and left ventricular diastolic function (23–25).
Beneficial effects of an augmented natriuretic peptide system
might also involve the suppression of the renin angiotensin
(26,27) and endothelin systems (28) as well as vascular and
cardiac antihypertrophic effects (29,30). Indeed, these mecha-
nisms may be particularly beneficial in patients with congestive
heart failure. In the current study population, only a small
subgroup was characterized by left ventricular dysfunction;
however, these subjects, when treated with beta-receptor an-
tagonists, were characterized by an increase in ANP by 22%
and BNP by 32% as compared to subjects with left ventricular
dysfunction not receiving such treatment. This finding should
be further evaluated in a prospective trial in patients with
congestive heart failure.
Study design. The current observational study harbors a
potential for bias by treatment indication because beta-
receptor antagonists are often prescribed in the presence of
factors which can affect cardiac natriuretic peptide concentra-
tions by themselves, particularly cardiac hypertrophy and left
ventricular dysfunction (31–34). To address this issue, we
employed three strategies. First, the association between beta-
receptor antagonism and natriuretic peptides in a number of
subgroups was studied. In fact, beta-receptor antagonism was
consistently associated with elevated ANP and BNP concen-
trations even in the absence of hypertension, left ventricular
hypertrophy, or left ventricular dysfunction. Next, this associ-
ation was examined in a multivariate regression model that
included a series of potential confounders. Beta-receptor
antagonism still remained an independent and significant
predictor of ANP, BNP and cGMP concentrations, and the
relative increases which appeared to be attributed to therapy
with beta-receptor antagonists were 121%, 182%, and 117%
for ANP, BNP and cGMP, respectively. Finally, when com-
pared with angiotensin-converting enzyme inhibition and di-
uretic therapy, the augmentation of ANP, BNP and cGMP was
specific for beta-receptor antagonism. In conjunction, recent
experimental data and the present analyses suggest that the
elevation of ANP, BNP and cGMP concentrations is directly
related to beta-receptor antagonism; nevertheless, given the
design of our study, this observation should be confirmed in
prospective placebo-controlled trials.
Conclusions. The current study provides new insights into
the interplay between the beta-adrenergic and the cardiac
natriuretic peptide system. ANP, BNP and cGMP concentra-
tions appear to be substantially augmented by use of beta-
receptor antagonists, independently of anthropometric param-
eters, cardiac structure, and function. The current data suggest
a possible contribution of the natriuretic peptide system to the
therapeutic spectrum of beta-receptor antagonism.
The authors acknowledge outstanding support by Michael Muscholl, MD and
Susanne Ku¨rzinger, BS.
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